Copyright
©The Author(s) 2024.
World J Clin Cases. Feb 16, 2024; 12(5): 995-1003
Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.995
Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.995
No | Ref. | Immunohistochemistry | Outcome | Follow-up |
1 | Lüttges et al[1] | CD34, CD99, Bcl-2, vimentin | Alive | 20 months |
2 | Chatti et al[8] | CD34, CD99, Bcl-2, vimentin | Death | 3 d |
3 | Gardini et al[9] | CD34, CD99, Bcl-2, vimentin, SMA | Alive | 16 months |
4 | Miyamoto et al[10] | CD34, Bcl-2 | Alive | 7 months |
5 | Kwon et al[11] | CD34, CD99, vimentin | NA | NA |
6 | Srinivasan et al[12] | CD34, Bcl-2 | Alive | 7 months |
7 | Chetty et al[13] | CD34, CD99, Bcl-2 | 42 mo | 6 v |
8 | Ishiwatari et al[14] | CD34, Bcl-2 | Alive | 42 months |
9 | Sugawara et al[15] | CD34 | NA | NA |
10 | Santos et al[16] | CD34, betacatenin | NA | NA |
11 | Tasdemir et al[17] | CD34, Bcl-2, beta-catenin, vimentin, Ki67 < 2% | Alive | 3 months |
12 | van der et al[18] | CD34, CD99, Bcl-2 | NA | NA |
13 | Chen et al[19] | CD34, Bcl-2, vimentin, CD68, muscle-specific actin | Alive | 30 months |
14 | Hwang et al[20] | CD34, Bcl-2, muscle-specific actin, CD10, ER, PR | Alive | 30 months |
15 | Baxter et al[21] | CD34, Bcl-2 | NA | NA |
16 | Estrella et al[22] | CD34, Bcl-2, keratin (rare), p16, p53 | Alive | 40 months |
17 | Han et al[23] | CD34, CD99 | No progression | 10 months |
18 | Murakami et al[24] | STAT6, CD34, Bcl-2, ACTH, POMC, NSE | Death | 4 months |
19 | Spasevska et al[3] | CD34, vimentin, CD99, Bcl-2, nuclear betacatenin | Death | 1 wk |
20 | Paramythiotis et al[7] | CD34, CD99, Bcl-2 vimentin, S-100 | Alive | 40 months |
21 | D'Amico FE et al[25] | STAT6, CD34 | Alive | 24 months |
22 | Oana et al[26] | CD34, Bcl-2 | Alive | 36 months |
23 | Sheng et al[27] | CD34, vimentin, SMA, Ki67 < 3% | Alive | 12 months |
24 | Geng et al[28] | STAT6, CD34, Bcl-2, CD31, PHH-3, D2-40, Ki67 > 10% | Alive | 6 months |
25 | Qian et al[29] | STAT6, CD34, Bcl-2, Ki67 10% | Alive | 10 months |
26 | Rogers et al[30] | STAT6, CD34, Bcl-2, CD99 | Alive | 4 months |
27 | Taguchi et al[31] | STAT6, CD34, Bcl-2, vimentin, cytokeratin AE1/AE3 | Alive | 12 months |
28 | Jariwalla et al[32] | STAT6, CD34 | NA | NA |
29 | Marotti et al[33] | STAT6, CD34 | Alive | 6 months |
30 | Addeo et al[6] | STAT6, CD34, Bcl-2, Ki67 7% | NA | NA |
31 | Rodriguez et al[2] | STAT6 | Alive | 12 months |
32 | Jones et al[34] | STAT6, CD34 | Alive | 1 months |
33 | Liu et al[35] | CD34, STAT6, CD99 | Alive | 6 months |
34 | Present case | TAT6, CD34, Bc1-2, Vimentin, CD99, Ki67 40% | Alive | 3 months |
- Citation: Wang WW, Zhou SP, Wu X, Wang LL, Ruan Y, Lu J, Li HL, Ni XL, Qiu LL, Zhou XH. Imaging, pathology, and diagnosis of solitary fibrous tumor of the pancreas: A case report and review of literature. World J Clin Cases 2024; 12(5): 995-1003
- URL: https://www.wjgnet.com/2307-8960/full/v12/i5/995.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i5.995